---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-006027"
form_type: "8-K"
ticker: "BYSI"
cik: "0001677940"
company_name: "BeyondSpring Inc."
filed_at: "2025-09-23T23:59:59+00:00"
generated_at: "2026-05-17T05:53:15.592262+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SEED Therapeutics closes $30M Series A-3, FDA clears IND for lead RBM39 degrader

## Summary
- Second close of $6M completes $30M Series A-3; BeyondSpring to own ~38.03% on as-converted basis.
- FDA cleared IND for ST-01156 (RBM39); first-in-human trial expected Q1 2026.
- SEED has received ~$60M in equity and payments from Eli Lilly and Eisai partnerships.
- BeyondSpring expects to continue consolidating SEED as it retains substantive control.

## SEC filing metadata
- accession: 0001171843-25-006027
- form_type: 8-K
- ticker: BYSI
- cik: 0001677940
- company_name: BeyondSpring Inc.
- filed_at: 2025-09-23T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677940/000117184325006027/0001171843-25-006027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677940/000117184325006027/f8k_092225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-006027
- JSON: https://secwatch.observer/filing/0001171843-25-006027.json
- Plain text: https://secwatch.observer/filing/0001171843-25-006027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.